NASDAQ: DMAC - DiaMedica Therapeutics Inc.

六个月盈利: +28.51%
股息率: 0.00%
部门: Healthcare

促销时间表 DiaMedica Therapeutics Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.

更多详情
The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2008-01-04
ISIN CA25253X2077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.diamedica.com
Цена ао 5.67
每日价格变化: +1.76% (5.67)
每周价格变化: +0% (5.77)
每月价格变化: -8.12% (6.28)
3个月内价格变化: +7.25% (5.38)
六个月内的价格变化: +28.51% (4.49)
每年价格变化: +90.43% (3.03)
3年内价格变化: +121.07% (2.61)
5年内价格变化: +25.43% (4.6)
年初以来价格变化: +18.48% (4.87)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 1.82 8
P/E 0 0
EV/EBITDA -4.18 0
全部的: 3.5

效率

姓名 意义 年级
ROA, % -35.78 0
ROE, % -37.96 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0188 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 1375.75 10
盈利能力 Ebitda, % 80.45 9
盈利能力 EPS, % -33 0
全部的: 7.6
更多详情

机构 体积 分享, %
Cooperman, Leon G. 883623 2.33
Vanguard Group Inc 802171 2.11
Paragon Associates & Paragon Associates Ii Joint Venture 500000 1.32
Altium Capital Management, LP 287698 0.76
Bleichroeder LP 222317 0.59
Geode Capital Management, LLC 218778 0.58
Jacob Asset Management Of New York LLC 168730 0.44
Northern Trust Corporation 133633 0.35
Morgan Stanley 120995 0.32
First Manhattan Company 114744 0.3

ETF分享, %本年盈利能力, %股息, %
iShares Micro-Cap ETF 0.02526 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.00098 27.77 1.68271
0.0122.431.61



导师 职称 支付 出生年份
Mr. Dietrich John Pauls MBA President, CEO & Director 818.61k 1971 (54 年)
Mr. Scott Kellen CPA CFO & Corporate Secretary 485.43k 1965 (60 年)
Dr. Ambarish Shah Ph.D. Chief Technology Officer N/A
Mr. Dominic R. Cundari Chief Commercial Officer N/A 1951 (74 年)
Mr. David J. Wambeke Chief Business Officer N/A 1984 (41 年)
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer N/A 1961 (64 年)

地址: United States, Minneapolis. MN, 301 Carlson Parkway - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.diamedica.com